Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479-Reference-Cited by-同舟云学术

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479

Published:2014-10 Issue:19 Volume:24 Page:4714-4723
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Robarge Kirk D.,Lee Wendy,Eigenbrot Charles,Ultsch Mark,Wiesmann Christian,Heald Robert,Price Steve,Hewitt Joanne,Jackson Philip,Savy Pascal,Burton Brenda,Choo Edna F.,Pang Jodie,Boggs Jason,Yang April,Yang Xioaye,Baumgardner Matthew

Funder

Department of Energy’s (DOE) Office of Science

DOE’s Office of Biological and Environmental Research

National Institutes of Health (NIH)

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference23 articles.

1. Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions

2. Targeting RAS signalling pathways in cancer therapy

3. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website